From: Immunotherapy Bridge 2018 and Melanoma Bridge 2018: meeting abstracts
Variable (comparator) | Progression free survival | |||
---|---|---|---|---|
Univariate analysis | Multivariate analysis | |||
HR (95% CI) | p-value | HR (95% CI) | p-value | |
BMI (< 25 vs ≥ 25) | 1.71 (1.09–2.67) | 0.0182 | 1.73 (1.09–2.74) | 0.0184 |
Primary tumor (NSCLC) | ||||
 Melanoma | 0.53 (0.29–0.99) | 0.0463 | 0.48 (0.26–0.91) | 0.0236 |
 Kidney | 0.75 (0.39–1.43) | 0.3880 | 0.59 (0.31–1.48) | 0.1223 |
 Others | 0.77 (0.27–2.13) | 0.6191 | 0.80 (0.28–2.23) | 0.6715 |
Sex (Male vs Female) | 1.23 (0.76–1.99) | 0.3881 | 1.15 (0.71–1.87) | 0.5734 |
Age (Elderly vs Non-elderly) | 1.04 (0.66–1.61) | 0.8570 | – | – |
Treatment line (Non-first vs First) | 1.72 (0.96–3.06) | 0.0639 | – | – |
Burden of disease (> 2 vs ≤ 2 sites) | 1.20 (0.75–1.92) | 0.4295 | – | – |
ECOG PS (≥ 2 vs 0–1) | 2.29 (1.86–4.70) | < 0.0001 | 2.94 (1.84–4.69) | < 0.0001 |